Lv3
218 积分 2022-01-21 加入
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
1天前
待确认
Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial
16天前
已完结
HER2-targeted therapies — a role beyond breast cancer
16天前
已完结
Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies
29天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
1个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
1个月前
已完结
Second-Line Therapy for Endometrial Cancer: The Need for Better Options
1个月前
已完结
PARP Inhibitors for Breast Cancer Treatment
2个月前
已完结
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM 2802)
3个月前
已完结
Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
3个月前
已完结
皖公网安备34019202002308
